Ajanta Pharma Limited has announced that its Board of Directors will convene on November 3, 2025, to deliberate on several key financial matters, including the declaration of the company's first interim dividend for the fiscal year ending March 31, 2026.

Key Points of the Announcement

• Board Meeting Date: November 3, 2025
• Agenda Items:
  • Consider declaring the first interim dividend for FY 2025-26
  • Review unaudited financial results for Q2 and H1 FY 2025-26
  • Potentially fix the record date for dividend payment

Dividend Considerations

The pharmaceutical company has informed the stock exchanges that if an interim dividend is declared, the Board will consider setting November 10, 2025, as the record date for determining shareholder eligibility.

Financial Review

In addition to the dividend deliberation, the Board meeting will focus on reviewing the company's financial performance. The agenda includes:

• Examination of unaudited financial results for the second quarter (Q2) of FY 2025-26
• Review of half-yearly (H1) financial results ending September 30, 2025

Regulatory Compliance

Ajanta Pharma's announcement aligns with regulatory requirements, as stated in their official communication:

"Pursuant to Regulation 29(1)(e) and 42 of the Listing Regulations, we hereby inform you that, at the aforesaid Board Meeting, the Board of Directors will also consider: a. declaration of 1st interim dividend for the financial year ending 31st March 2026; and b. fixation of Monday, 10th November 2025 as the Record Date for the payment of interim dividend, if declared."

Investor Implications

Shareholders and potential investors should mark these dates:

Investors are advised to monitor the outcome of this board meeting, as it may impact the company's stock price and provide insights into Ajanta Pharma's financial health and shareholder return policies.

The company has requested the stock exchanges to disseminate this information to all concerned parties, ensuring transparency and compliance with market regulations.

Ajanta Pharma Limited , a prominent player in the pharmaceutical sector, has seen continued share pledging activities by its promoters. Recent disclosures show updated transactions by key promoter Aayush Agrawal, along with previous activities by Ravi Agrawal.

Latest Aayush Agrawal Share Pledge Update

In the most recent disclosure dated December 17, 2025, Aayush Agrawal reported simultaneous pledge creation and release activities. The transactions involved:

Following these latest transactions, the Aayush M Agrawal Trust's total encumbered shareholding stands at 69,68,247 shares, representing 5.58% of the total share capital.

Previous Aayush Agrawal Transactions

Earlier, Aayush Agrawal had pledged 6,45,000 shares for new loan and additional margin purposes, disclosed on October 1, 2025. Those pledges were created with multiple financial institutions including Deutsche Investments India Pvt Ltd, HSBC InvestDirect Financial Services India Ltd, and Jio Finance Ltd.

Ravi Agrawal's Share Transactions

In a separate disclosure dated October 3, 2025, Ravi Agrawal, another promoter of Ajanta Pharma, reported both creation and release of pledges:

Significant transactions included pledge creation of 10,50,000 shares with Emerging India Credit Opportunities Fund for business financing, along with multiple smaller transactions with Bajaj Finance Ltd, Barclays Investment, Infina Finance Ltd, and Aditya Birla Capital Limited.

Current Promoter Holdings Summary

Following all disclosed transactions, the promoter encumbered shareholdings are:

These pledging activities by the promoters are part of their ongoing financial management strategies and represent routine corporate financing activities. The transactions demonstrate active portfolio management while maintaining significant promoter involvement in the company.